Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen

September 19, 2016 9:51 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Sarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen

Letter from FDA

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Hot FDA News, Management Changes, Trader Talk

Add Your Comment